SPOTLIGHT: Cell Therapeutics buys cancer drug
Cell Therapeutics has agreed to shell out $10 million up front and up to $20 million in milestones for the marketing and development rights of Biogen Idec's Zevalin, a cancer drug. The milestones kick in with the drug's approval as a first-line treatment for non-Hodgkin's lymphoma. Release
Be the first to comment
More stories about cancer drug sales and marketing non-Hodgkin's lymphoma milestones Biogen Idec lymphoma Cell Therapeutics
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
